<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891250</url>
  </required_header>
  <id_info>
    <org_study_id>ZIT</org_study_id>
    <nct_id>NCT04891250</nct_id>
  </id_info>
  <brief_title>The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19</brief_title>
  <acronym>ZIT</acronym>
  <official_title>The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Infectious Disease Research in Zambia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Infectious Disease Research in Zambia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to test whether Ivermectin would decrease mortality and reduces chances of&#xD;
      getting infected with corona virus, improve management of clinical symptoms and reduce length&#xD;
      of stay in ICU and transition probabilities to ICU (ventilator).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the onset of global pandemic of the Severe Acute Respiratory Syndrome Coronavirus 2&#xD;
      (SARS-CoV-2) and the sharp rise in infection and mortality rates, efficient management of the&#xD;
      current medical emergency has become an absolute priority. A lot of resources have been&#xD;
      directed to developing a comprehensive therapeutic approach to preventing and curing this&#xD;
      disease, and this has mostly been in western countries. However, lack of definite treatment,&#xD;
      high number of infected people, limited capacity and the impact of COVID-19 on existing&#xD;
      health infrastructure has left biomedical researchers and clinicians faced with the mammoth&#xD;
      task of providing appropriate clinical care solutions and strategies with favorable&#xD;
      cost-benefit outcomes, which can help in both curbing the disease and treating patients. To&#xD;
      meet this challenge, repurposing of available drugs has become vital. Evidence from several&#xD;
      recent clinical trials on the effects of available therapeutic clinical drugs and vitamin&#xD;
      supplements on mortality rate and other clinical outcomes associated with COVID-19 are&#xD;
      promising, however, the efficacy, safety, and appropriate dosing of therapeutic clinical&#xD;
      drugs such as ivermectin, remain largely unevaluated in Sub-Saharan Africa. The investigators&#xD;
      propose to evaluate and compare the efficacy of ivermectin in the management of Covid-19.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause COVID-19 related mortality</measure>
    <time_frame>within 28 days of enrollment</time_frame>
    <description>All-cause COVID-19 related mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>COVID-19 Infection</measure>
    <time_frame>Study duration</time_frame>
    <description>the proportion of patients on Ivermectin prophylaxis who test positive for COVID 19 using PCR after initially testing negative at enrolment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient cure rate</measure>
    <time_frame>14- 28 days</time_frame>
    <description>The percentage of cured patients, defined as symptoms free to be discharged from the hospital and the percentage Changes of WHO's OSCI scale for COVID-19 between baseline and day 14 and between baseline and day 28. The study will will also evaluate the time to cure in both groups by measuring time from admission of the patient to the hospital till discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Infection Rate</measure>
    <time_frame>90 days</time_frame>
    <description>determine proportion who will develop severe disease and needing admission in addition to the above outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>SARS-CoV-2</condition>
  <condition>Ivermectin</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate to severe COVID-19 disease will be randomized to either Ivermectin (Intervention) or Standard of Care (Control arm) in a 1:1 ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An additional group of patients will be recruited will be randomized to either Ivermectin as prophylaxis (Intervention) or Standard of Care with no ivermectin (Control arm) in a 1:1 ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Treatment of SARS Cov-2 patients with Ivermectin</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prophylaxis</intervention_name>
    <description>Treatment of high risk population with Ivermectin as prophylaxis</description>
    <arm_group_label>Prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals diagnosed positive for SARS-CoV-2 by real-time reverse transcription PCR&#xD;
             (rRT-PCR with presence of a fever, cough, and/or sore throat.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded if they report to be allergic to ivermectin or if there is&#xD;
             potential for a drug-drug interaction with ivermectin;&#xD;
&#xD;
          -  Have chronic illnesses (e.g., ischemic heart disease, heart failure, documented&#xD;
             cardiomyopathy, chronic kidney disease, chronic liver disease);&#xD;
&#xD;
          -  Have received ivermectin in the last 7 days; are pregnant or lactating;&#xD;
&#xD;
          -  Or have participated in any other clinical trial within the last month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wilbroad Mutala, PhD</last_name>
    <phone>+260967780284</phone>
    <email>wmutale@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Zambia</name>
      <address>
        <city>Lusaka</city>
        <zip>10101</zip>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <reference>
    <citation>Annweiler C, Beaudenon M, Gautier J, Simon R, Dubée V, Gonsard J, Parot-Schinkel E; COVIT-TRIAL study group. COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. Trials. 2020 Dec 28;21(1):1031. doi: 10.1186/s13063-020-04928-5.</citation>
    <PMID>33371905</PMID>
  </reference>
  <reference>
    <citation>Jovanović A, Klimek P, Renn O, Schneider R, Øien K, Brown J, DiGennaro M, Liu Y, Pfau V, Jelić M, Rosen T, Caillard B, Chakravarty S, Chhantyal P. Assessing resilience of healthcare infrastructure exposed to COVID-19: emerging risks, resilience indicators, interdependencies and international standards. Environ Syst Decis. 2020 Jun 4:1-35. doi: 10.1007/s10669-020-09779-8. [Epub ahead of print]</citation>
    <PMID>32837821</PMID>
  </reference>
  <reference>
    <citation>Chaccour C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F, Giráldez M, Laso E, Gabaldón-Figueira JC, Dobaño C, Moncunill G, Yuste JR, Del Pozo JL, Rabinovich NR, Schöning V, Hammann F, Reina G, Sadaba B, Fernández-Alonso M. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021 Feb;32:100720. doi: 10.1016/j.eclinm.2020.100720. Epub 2021 Jan 19.</citation>
    <PMID>33495752</PMID>
  </reference>
  <reference>
    <citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.</citation>
    <PMID>32251768</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.</citation>
    <PMID>32289548</PMID>
  </reference>
  <reference>
    <citation>Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020 Sep;73(9):593-602. doi: 10.1038/s41429-020-0336-z. Epub 2020 Jun 12.</citation>
    <PMID>32533071</PMID>
  </reference>
  <reference>
    <citation>Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021 Feb;103:214-216. doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.</citation>
    <PMID>33278625</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

